Nuvation Bio Inc (NUVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nuvation Bio Inc (NUVB) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Nuvation Bio reported EPS of -$0.12, below the -$0.11 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NUVB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
NUVB Earnings Call
The latest NUVB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, NUVB beat 13, missed 7 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $44.95M, up 242.6% from $13.12M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.11 | -$0.13 - -$0.09 | -9.09% | Miss | N/A | 3 | 0 up, 1 down | Nov 4, 2026 | $44.95M |
| Jun 30, 2026 | -$0.15 | -$0.15 | N/A | 0.00% | In line | N/A | 1 | 0 up, 1 down | Aug 6, 2026 | $31.69M |
| Mar 31, 2026 | $0.01 | -$0.04 | N/A | +123.15% | Beat | N/A | 1 | 0 up, 0 down | May 4, 2026 | $83.23M |
| Dec 31, 2025 | -$0.11 | -$0.09 | N/A | -22.22% | Miss | N/A | 2 | 0 up, 0 down | Mar 2, 2026 | $41.87M |
| Sep 30, 2025 | -$0.16 | -$0.17 | N/A | +5.88% | Beat | N/A | 1 | 0 up, 0 down | Nov 3, 2025 | $13.12M |
| Jun 30, 2025 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | 1 | 0 up, 1 down | Aug 7, 2025 | $4.83M |
| Mar 31, 2025 | -$0.13 | -$0.12 | -$0.13 - -$0.11 | -8.33% | Miss | N/A | 2 | N/A | May 7, 2025 | $3.08M |
| Dec 31, 2024 | -$0.12 | -$0.12 | -$0.14 - -$0.10 | +2.92% | Beat | N/A | 2 | 1 up, 0 down | Mar 6, 2025 | N/A |
| Sep 30, 2024 | -$0.12 | -$0.10 | -$0.18 - -$0.08 | -20.00% | Miss | N/A | 5 | 1 up, 0 down | Nov 6, 2024 | $727000 |
| Jun 30, 2024 | -$1.85 | -$0.05 | -$0.07 - -$0.05 | N/A | N/A | N/A | 6 | 0 up, 0 down | Aug 5, 2024 | $1.44M |
| Mar 31, 2024 | -$0.04 | -$0.05 | N/A | +20.00% | Beat | N/A | 5 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.06 | -$0.10 | -$0.13 - -$0.09 | +40.00% | Beat | N/A | 6 | 0 up, 0 down | Feb 29, 2024 | $264000 |
| Sep 30, 2023 | -$0.06 | -$0.08 | N/A | +25.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.07 | -$0.08 | N/A | +12.50% | Beat | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.08 | -$0.06 | N/A | -33.33% | Miss | N/A | 6 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.10 | -$0.11 | -$0.14 - -$0.08 | +9.09% | Beat | N/A | 6 | 0 up, 0 down | Mar 15, 2023 | N/A |
| Sep 30, 2022 | -$0.11 | -$0.15 | -$0.17 - -$0.11 | +26.67% | Beat | N/A | 7 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$0.14 | -$0.11 | N/A | -27.27% | Miss | N/A | 6 | 0 up, 0 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$0.08 | -$0.13 | N/A | +38.46% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | -$0.12 | -$0.12 | -$0.13 - -$0.11 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Feb 28, 2022 | N/A |
| Sep 30, 2021 | -$0.09 | -$0.10 | -$0.12 - -$0.10 | +10.00% | Beat | N/A | 5 | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$0.08 | -$0.10 | -$0.12 - -$0.08 | +20.00% | Beat | N/A | 5 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$0.11 | -$0.06 | -$0.10 - -$0.05 | -83.33% | Miss | N/A | 6 | N/A | May 17, 2021 | N/A |
| Dec 31, 2020 | -$0.04 | -$0.05 | -$0.06 - -$0.04 | +20.00% | Beat | N/A | 3 | N/A | Jan 20, 2021 | N/A |
| Sep 30, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2020 | N/A |
| Jun 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 14, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.57, after -$2.13 the year before. It was -$0.08 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.57 | N/A |
| Dec 31, 2024 | -$2.13 | N/A |
| Dec 31, 2023 | -$0.27 | N/A |
| Dec 31, 2022 | -$0.43 | N/A |
| Dec 31, 2021 | -$0.40 | N/A |
| Dec 31, 2020 | -$0.08 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,000 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,040 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,773 | 13 | |
| 2026Q1 | Mar 31, 2026 | 6,731 | 8 | |
| 2025Q4 | Dec 31, 2025 | 9,328 | 12 | |
| 2025Q3 | Sep 30, 2025 | 8,243 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,264 | 11 |
2026Q3 Earnings Call
Opening remarks
Robert DeVita Vice President of Corporate Development and Investor Relations Thank you, and good afternoon, everyone. Earlier today, we issued a press release summarizing our financial results for the quarter ending September 30, 2026, and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, our development plans for taletrectinib, safusidenib, and our drug-drug conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue, our expected milestone payments and spending patterns, and our cash runway and profitability potential. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10-Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our Founder, President and Chief Executive Officer, Dr. David Hung; our Chief Commercial Officer, Colleen Sjogren; and our Chief Financial Officer, Philippe Sauvage. Now I'll turn the call over to Dr. David Hung. David, please go ahead.
David Hung Founder, President and Chief Executive Officer Thanks, J.R. Good afternoon, everyone, and thank you all for joining us. Today, I'm pleased to discuss the progress we made across our business in the third quarter. We generated $45 million in overall revenue, driven by another quarter of strong IBTROZI growth. Net U.S. IBTROZI product revenue was $27.5 million, which represented 18% growth from the last quarter. Approximately 160 new patients started treatment with IBTROZI, about 65% of which were in the first-line setting. The commercial signals that matter most to our long-term thesis remain encouraging. Fifteen months into our U.S. launch, we continue to both build a growing base of patients on therapy and strengthen our position in the ROS1 market. IBTROZI has reached an all-time high in its share of active patients receiving a ROS1 TKI and continues to lead in first-line new patient starts with greater than 60% market share as of the end of the quarter. Our revenue growth reflects an expanding active treatment base driven by an increasing proportion of first-line patients that we believe can stay on therapy for years, as seen in our TRUST clinical studies. IQVIA claims data from the third quarter demonstrated a 15% decline in total new patient starts across the ROS1 TKI market. This is further evidenced by a lower volume of ROS1-positive testing alerts from our laboratory data partners.
Frequently Asked Questions About NUVB
Did NUVB beat earnings estimates last quarter?
No. Nuvation Bio reported EPS of -$0.12 for the quarter ended Sep 30, 2026, below the -$0.11 estimate by 9.09%.
What EPS do analysts expect from NUVB next quarter?
The consensus EPS estimate for Nuvation Bio for the quarter ending Dec 31, 2026 is -$0.11 from 15 analysts, with estimates from -$0.14 to -$0.03.
How often does NUVB beat earnings estimates?
Nuvation Bio beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +11.54%.
NUVB pages: Overview, Earnings, Forecast, Financials, Competitors